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Abstract
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect on
symptom reduction and on general well being of patients suffering from psychosis. However, questions regarding
the specific efficacy of CBT, the treatment safety, the cost-effectiveness, and the moderators and mediators of
treatment effects are still a major issue. The major objective of this trial is to investigate whether CBT is specifically
efficacious in reducing positive symptoms when compared with non-specific supportive therapy (ST) which does
not implement CBT-techniques but provides comparable therapeutic attention.
Methods/Design: The POSITIVE study is a multicenter, prospective, single-blind, parallel group, randomised clinical
trial, comparing CBT and ST with respect to the efficacy in reducing positive symptoms in psychotic disorders. CBT
as well as ST consist of 20 sessions altogether, 165 participants receiving CBT and 165 participants receiving ST.
Major methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of
assessments with control for rater shift, analysis by intention to treat, data management using remote data entry,
measures of quality assurance (e.g. on-site monitoring with source data verification, regular query process),
advanced statistical analysis, manualized treatment, checks of adherence and competence of therapists.
Research relating the psychotherapy process with outcome, neurobiological research addressing basic questions of
delusion formation using fMRI and neuropsychological assessment and treatment research investigating
adaptations of CBT for adolescents is combined in this network. Problems of transfer into routine clinical care will
be identified and addressed by a project focusing on cost efficiency.
Discussion: This clinical trial is part of efforts to intensify psychotherapy research in the field of psychosis in
Germany, to contribute to the international discussion on psychotherapy in psychotic disorders, and to help
implement psychotherapy in routine care. Furthermore, the study will allow drawing conclusions about the
mediators of treatment effects of CBT of psychotic disorders.
Trial Registration: Current Controlled Trials ISRCTN29242879
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Positive symptoms and cognitive behavioural therapy
In the last two decades cognitive behavioural therapy
(CBT) approaches for patients with schizophrenia have
been developed which are specifically designed to reduce
severity of positive symptoms. Positive symptoms such
as persecutory delusions and hallucinations, which inter-
fere with the patient’s ability to maintain social relation-
ships, cause serious distress and life disruption in
patients as well as in relatives. They represent hallmark
symptoms of psychosis in the schizophrenia spectrum
disorders. Even with advances in pharmacological treat-
ments for schizophrenia and other psychotic disorders
there is a large subgroup of patients characterised by
nonresponse to antipsychotic treatment. Leucht et al. [1]
report nonresponse rates between 38% and 76% even
when second generation antipsychotic agents are
prescribed.
Against this background the investigation of other
treatment approaches which may have the potential to
reduce positive symptoms has high priority. It has been
demonstrated that cognitive behavioural treatment
(CBT) has a moderate effect on symptom reduction and
on general well being of patients suffering from psycho-
sis. The most recent meta-analyses [2,3] state that the
effect size of CBT is .37 for the reduction of positive
symptoms. Based on the earlier meta-analysis of Pilling
et al. [4] the British National Institute of Clinical Excel-
lence recommended CBT for routine care. In the mean-
time, also in other countries like Germany [5], CBT is a
recommended treatment modality for symptom
reduction.
Open questions
However, many important questions remain unan-
swered, even if the efficacy of CBT for symptom reduc-
tion is increasingly well established.
1. CBT for psychosis has been specifically developed
for the reduction of positive symptoms. However, in
contrast to more recent meta-analyses the Cochrane
meta-analysis of Jones et al. [6] did not find significant
reduction of positive symptoms indicating that more
large scale clinical trials are needed. Wykes et al. [2]
showed a significant heterogeneity in their meta-analysis
which might point to unknown moderator effects. In
particular the evidence for the specific efficacy of CBT
should be improved. When compared to Supportive
Treatment, CBT could not as yet demonstrate clear
superiority.
2. Patients with psychotic disorders might conceivably
experience symptom exacerbation or suicidal crises as a
consequence of psychotherapeutic efforts. Negative
effects should actively be sought in order to demonstrate
safety of the treatment. Therefore, Jones et al. [6]
recommended investigating adverse events in CBT trials.
However, Tarrier et al. [7] investigated suicidality in
CBT-trials and did not find any indication for an
increased rate of suicide attempts. More data about
treatment safety would be helpful for implementation of
CBT, as scepticism among clinicians is widespread.
3. Wykes et al. [2] found that outcome in CBT trials is
associated with methodological rigor. Thus, more clini-
cal trials applying rigorous methodology are needed in
order to investigate whether treatment effects are stable
even in high quality studies.
4. Psychotic disorders, in particular schizophrenia, are
causing a considerable economic burden, e.g. in terms
of costs of care. As resources for health care a limited,
the cost-effectiveness of single health services increas-
ingly gains importance. CBT for psychotic symptoms is
currently not available for a majority of patients due to
therapeutic scepticism and limited resources. Against
this background the question of cost-effectiveness
should urgently be addressed.
5. Psychological theories of delusions emphasize either
altered attention (selectively attending to evidence in
favour of the delusions), or disturbances in making
unbiased inferences [8]. There are findings that patients
with persecutory delusions preferentially attend threat
related stimuli or threat to the subject’ss e l fc o n c e p t
[9,10]. Theory-of-mind skills and attributional style
together with social perception (i.e. social cue percep-
tion and facial affect recognition) are considered as
the main sub-processes of social cognition [11]. The
evidence in support of these hypotheses is limited and
should be increased.
6. The identification of moderators and mediators of
treatment effects is a major issue for further develop-
ment of treatment strategies. However, it has as yet
not been studied whether CBT, if successful, alter
these biases towards normality [12], and whether the
success of CBT critically depends on cognitive and
social-cognitive skills. Treatment effects on neurocog-
nitive plasticity have thus far only been described for
“cognitive remediation” therapy in one fMRI working
memory study with 6 patients. After therapy, a differ-
ential activation in the lateral frontal lobe has been
demonstrated [13]. Well described cognitive limitations
or deficits, e.g. of declarative memory and attention
span, arise from enduring (trait) and transient (state)
neurobiological alterations in schizophrenia patients,
with considerable variation being present between sub-
jects. Such cognitive limitations underlie the develop-
ment of specific symptoms [e.g. delusions, [14]], are
correlated with the degree of insight [15], and are lim-
iting the success of any therapy which, like CBT, is
based on verbal learning and requires sufficient atten-
tion. Process-outcome research in psychotherapy
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aspects of the therapeutic process are particularly help-
ful or harmful to patients [16]. This research links the
two domains of process and outcome studies. Orlinsky
et al. [16] view the therapeutic contract (treatment
model, e.g. rational, goal setting, format), the therapeu-
tic operations (therapist interventions), and the thera-
peutic bond (therapist’sa n dp a t i e n t ’si n t e r p e r s o n a l
behaviour) as the essential factors of the treatment
process. These factors were empirically found to be
linked with therapy outcome in many psychiatric dis-
orders. However, regarding psychotherapy in psychotic
disorders, such findings are still missing up to now.
With respect to CBT for positive symptoms in psycho-
tic disorders process-outcome research is not yet a
major focus. Studies on this topic focus mainly on
effectiveness [e.g. [17-19]].
Objectives
The major objective of this trial is to investigate whether
CBT is specifically efficacious in reducing positive symp-
toms when compared with non-specific supportive treat-
ment (ST) which does not implement CBT-techniques
but provides comparable therapeutic attention.
The trial is accompanied by research addressing (a)
process-outcome-relationship dedicated to illuminat-
ing the question of the active ingredients in CBT and
(b) neurobiological factors of delusion formation using
functional magnetic resonance imaging (fMRI) and
neuropsychological assessment, as well as (c) treat-
ment research investigating adaptations of CBT in
adolescents. Finally (d) problems in relation to disse-
minating and establishing findings in routine care will
be identified and addressed by a project on cost-
effectiveness.
Methods/Design
General design aspects
This study is a multicenter, prospective, single-blind,
parallel group, randomised clinical trial (principal inves-
tigator(PI): SK), comparing CBT and ST with respect to
the efficacy in reducing positive symptoms in psychotic
disorders at nine months after inclusion. The study
includes patients with persistent positive symptoms in
six study centers applying a systematic recruitment
strategy. CBT as well as ST consist of 20 sessions alto-
gether, 165 participants receiving CBT and 165 partici-
pants receiving ST (Table 1). The duration of treatment
for each study patient will be approximately 36 weeks
(i.e., 9 months). The study will be conducted in accor-
dance to GCP and CONSORT. The study has received
approval from the local ethics committees and is carried
out in accordance with the latest version of the Declara-
tion of Helsinki.
Process of recruitment and obtaining written informed
consent
The recruitment for this study will address the catch-
ment area of the participating institutions (Departments
of Psychiatry and Psychotherapy of the Universities of
Bonn (PI: MW), Düsseldorf (PI: WW), Essen (PI: BM
and GS), Frankfurt (PI: GW and JH), Köln (PI: AB), and
Tübingen (PI: SK) with their associated inpatient and
outpatient facilities). It aims at implementing a systema-
tic recruitment plan which will be documented accord-
ing to CONSORT. For every screened patient the
inclusion and exclusion criteria will be recorded. All
patients who fulfil the inclusion criteria will be offered
to participate in this study. Thus, the resulting sample
should represent a geographic cohort.
Under conditions of routine care the patient popula-
tion addressed by this trial is treated in psychiatric hos-
pitals in case of acute exacerbations, and psychiatric
outpatient facilities. In addition, patients are cared for
by a considerable number of social psychiatric institu-
tions for supported housing, supported work, and other
social psychiatric services.
For the duration of the recruitment phase all inpati-
ents of the participating institutions with psychotic
disorders will be screened for their eligibility before dis-
charge from hospital. Information about the study will
be provided to the respective patients whenever possible.
Table 1 Study design
Study condition CBT
Cognitive Behavioural Therapy
(+ standard care)
ST
Supportive Treatment
(+ standard care)
Major inclusion criteria Patients with psychotic disorders, PANSS-Delusion or - Hallucination ≥ 4, symptoms
persistent for at least 3 months
N = 330
(to be included in six study centres)
165 165
Study treatment sessions (treatment duration 9 months) 20 20
Primary Outcome Positive Symptoms (PANSS) at post treatment assessment (nine months after inclusion)
post treatment follow-up 24 month
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take place. In outpatient departments a complete
screening will be conducted for intervals of three
months in order to implement comparable strategies for
systematic recruitment. In addition, recruitment can
also take place in other outpatient services and practices
as well as in institutions for supported housing or
supported employment. Again, systematic recruitment
strategies will be applied.
The registration procedurew i l lb ec o n d u c t e df o ra l l
patients with a tentative diagnosis of a psychotic disor-
der (see Figure 1, 2, 3). Patients without “obvious”
exclusion criteria (e.g. age, foreign language, living out-
side of the catchment area, substance dependency as
primary problem, mental retardation, ongoing outpatient
psychotherapy) will be approached and offered to be
informed about the study.
In case of refusal, the patient will be asked whether he
is willing to give reasons for refusal and to allow for
symptom assessment (PANSS) at the time of refusal.
For this purpose a separate patient information and con-
sent form will be applied. Only after giving consent for
this interview the reasons for refusal from the viewpoint
of the patient and the current symptomatic status will
be assessed and recorded. If the patient does not give
his consent to be interviewed for his reasons of refusal,
the staff member who has provided the information
about the trial will give his opinion about the major
reason.
In a first appointment potentially eligible patients will
be informed about the study using the written patient
information. In in-patients study information can be pro-
vided in the hospital. The written patient information
will be handed out when the patient signifies interest in
study participation. In each case, obtaining written
consent will take place at the beginning of a second
appointment prior to inclusion examination. This second
appointment has to take place in an out-patient setting in
order to ensure the patient’s willingness to start outpati-
ent treatment. If patients have by law a care giver respon-
sible to provide support for the patient regarding health
related decisions, patients can only be included in the
trial if both the patient and the care giver give their
informed consent. The care giver will be asked to show
the staff member responsible for inclusion his/her certifi-
cate of appointment.
For every screened patient a paper based screening
and randomisation form will be filled in and faxed to
the Coordination Centre of Clinical Trials (CenTrial).
The screening and randomisation form will include a
list of questions to be answered during the registration
procedure. In particular, the inclusion and exclusion cri-
teria will be recorded. Patient screening and randomisa-
tion will only be accepted from authorized investigators.
At the end of the screening and randomisation form the
investigators will document the intended status of the
patient in the trial: (1) as patient to be included and
randomised, or (2) as patient not to be included but
screened (with or without participation in the refusal
survey).
Figure 1 Process of screening.
Figure 2 Informed consent and baseline examination (T0).
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In order to be included into the study, patients have to
meet diagnostic criteria of schizophrenia (DSM-IV
295.1, 295.2, 295.3, 295.6, 295.9), schizophreniform
disorder (DSM IV, 295.4), schizoaffective disorder
(DSM-IV 295.7), or delusional disorder (DSM IV 297.1),
confirmed by a structured clinical interview (SCID-I).
Essential for inclusion is moderate or severe symptom
intensity, i.e., a score of 4 or more, on the PANSS-items
“Delusions” (P1) or “Hallucinations” (P3). Furthermore,
t h ep r e s e n c eo fp o s i t i v es y m p t o m sf o ra tl e a s tt h r e e
months with or without compliance regarding antipsy-
chotic medication is necessary. Other inclusion criteria
are fluency regarding the German language, age between
18 and 59, a verbal IQ > 80 assessed by a multiple-
choice vocabulary test ("Mehrfachwahl Wortschatz Intel-
ligenz-Test”,M W T - B ,[ 2 0 ] ) ,a n dw i l l i n g n e s st og i v e
informed consent. Criteria for exclusion are any kind of
organic brain diseases (other than schizophrenia)
according to standard patient examination procedures
and diagnosis of substance abuse or substance depen-
dence according to DSM-IV/SCID-I as primary clinical
problem.
Randomization
All patients who give consent for participation and who
fulfil the inclusion criteria will be randomized. Randomi-
sation will be requested by the staff member responsible
for recruitment and clinical interviews from CenTrial.
In return, CenTrial will send an answer form to the
study therapist who is not involved in assessing outcome
of the study. This form will include a randomisation
number. In every centre closed envelopes with printed
randomisation numbers on it are available. For every
randomisation number the corresponding code for the
therapy group of the randomisation list will be found in
inside the envelopes. The therapist will open the envel-
ope and will find the treatment condition to be con-
ducted in this patient. The therapist then gives the
information about treatment allocation to the patient.
Staff responsible for recruitment and symptom ratings is
not allowed to receive information about the group
allocation.
As part of the efforts of quality assurance the correct-
ness of the randomisation procedure in each patient will
be monitored at the regular on-site visits.
The allocation sequence will be generated by the Insti-
tute for Medical Biometry (IMB) applying a permuted
block design with random blocks stratified by study cen-
tre and medication compliance (favourable vs. unfavour-
able). The blocks should provide comparable numbers
of patients in both conditions at any time in the course
of the study. The block size will be concealed until the
primary endpoint will be analysed. Throughout the
study, the randomisation will be conducted by CenTrial
in order to keep the data management and the statisti-
cian blind against the study condition as long as the
data bank is open. The randomisation list remains with
CenTrial for the whole duration of the study. Thus, ran-
domisation will be conducted without any influence of
the principal investigators, raters or therapists.
Blinding
This study implements a single blind design by comple-
tely separating treatment and assessment.
Therapists will not be involved in assessing the treat-
ment outcome. Raters will not be allowed to hold treat-
ment sessions. Patients will be informed about their
treatment allocation by the therapist but not by the
raters. Only therapists will receive information about
group allocation. Discussions about study patients are
not allowed between raters and therapists. These princi-
ples were part of the staff training.
At the beginning of every visit, the raters will instruct
the patient not to reveal their treatment condition and
not to talk about details of their treatment. The raters
will have to complete a “blindness protocol” after each
visit. Any unintentional disclosure of the treatment con-
dition will be documented. Further, the raters are asked
to guess the study condition of the patient after each
assessment. Among all documented guesses the rate of
correct guesses should not be significantly different
from chance (i.e. 50%).
In order to avoid any bias in data analyses data will be
primarily analysed by the intention-to-treat principle.
Figure 3 Randomization and begin of study therapy.
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independent statistician of the Institute for Medical Bio-
metry (IMB). The statistician is not involved in rando-
misation. The group variable (treatment allocation) will
not be included until all data checks are completed.
Even in case of severe adverse events no unblinding of
raters will be necessary. In these cases therapists will
start the appropriate crisis management strategies. If the
rater is the first staff member to detect an adverse event
he will give notice to the therapist who will implement
all appropriate measures.
Cognitive behavioural therapy
CBT for the treatment of positive symptoms in psychotic
disorders is based on general CBT principles. Participants
are regarded as active, self responsible individuals. During
all phases of the treatment patients are requested to
actively participate in the treatment and to take responsi-
bility for decisions how to proceed together with the
therapist. The therapeutic process rests on the coopera-
tion between patient and therapist. Whenever necessary,
the therapist modifies his intervention in order to help
the patient to engage in the therapeutic process.
Treatment is built on a case formulation: Patients and
therapist will engage in developing a shared definition of
the major problem of the patient. When providing infor-
mation about psychosis therapists will use a normalising
and non-stigmatising style of explanations. The formula-
tion has to address (explicitly or implicitly) persistent
positive symptoms. A shared formulation is thought to
be a necessary prerequisite for a successful treatment.
The specific problems to be addressed in CBT are delu-
sions and hallucinations. The treatment is aimed at
helping the patient cope with these symptoms. A major
principle of CBT is to link behaviour, emotion and cog-
nition in order to provide a detailed understanding of
the patient’s problems. Psychotic symptoms are under-
stood as result of dysfunctional ways of perceiving and
interpreting social situations. CBT aims at correcting
the person’s misperceptions, irrational beliefs and rea-
soning biases as well as at reducing the distress caused
by symptoms and the improvement of social function-
ing. Participants engage in monitoring own thoughts,
feelings and behaviours. They are encouraged to test
alternative ways of coping with the target symptom.
Strategies for the treatment of delusions and delusional
processing of hallucinations are to review the informa-
tion processing (perception bias, jumping to conclu-
sions, attributional bias, theory of mind deficit), to
engage in schema work in order to modify potentially
delusion related self schemata, to plan activities for rea-
lity testing which will provide evidence for or against
the delusional conviction, and to help patients reduce
the disruption of life and daily activities caused by the
delusions. Strategies to reduce hallucinations are to
improve the patients coping strategies (e.g. systematic
distraction strategies), and to identify and change social
or internal stimuli related with increased hallucinatory
experiences.
Major stages of CBT can be described as follows:
￿ Engagement (strategies to foster motivation for
treatment participation)
￿ Assessment (regarding symptoms and social
problems)
￿ Developing understanding of psychotic symptoms
using a “normalising” style of providing informa-
tion )
￿ Case formulation and treatment planning
￿ Specific techniques designed to address delusions
and hallucinations
￿ Specific techniques designed to address dysfunc-
tional beliefs and schemata
￿ Specific techniques designed to improve social
functioning
(See Figure 4)
The CBT manual of the POSITIVE study is published
in German language at the research network’s homepage
http://www.psychose-psychotherapieforschung.de
Supportive Therapy
ST will be used as comparator in order to control
for non-specific elements of therapeutic contact.
Psychotherapy outcome is generally thought of as con-
sisting of both specific and non-specific effects. Non-
specific effects like emotional support, therapeutic
attention, empathic listening, implementation of thera-
peutic optimism and others are the result of every
successful therapeutic relationship. In contrast, thera-
peutic outcome, which is directly linked to specific and
well-defined treatment strategies, is called specific effect.
It is hypothesised that CBT produces specific and non-
specific factors whereas ST should only result in non-
specific factors. ST does not rely on specific theories or
assumptions about the causes of positive symptoms in
psychotic disorders. ST will focus on the patients’
experiences and daily activities. The sessions will focus
on neutral topics, such as hobbies, sports, and current
affairs. Therapists will engage in listening to the patient,
in being empathic, in helping the patient structure the
available time and discussing problems in way friends
would do. Thus, ST is thought as an active treatment
with respect to the patient-therapist relationship and
with respect to therapeutic commitment [21]. In the
treatment of patients suffering from psychotic disorders
these ingredients are viewed to be essential as it has
been shown consistently that the social network of
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worthy person to talk to may be the most important
ingredient in any kind of treatment. However, with
respect to specific processes related to modification of
psychotic beliefs, ST is not an active treatment. Strate-
gies specifically designed to change misperceptions or
reasoning biases are not part of ST.
Major aspects of ST will be:
￿ Engagement
￿ Assessment of social problems and interests of the
patient
￿ Treatment planning
￿ Focus on housing, work, leisure time, hobbies, and
events, as adequate.
Psychotic or affective symptoms will not directly be
tackled in any way. (See Figure 5)
The ST manual of the POSITIVE study is also pub-
lished at the research network’s homepage http://www.
psychose-psychotherapieforschung.de.
Formal characteristics of study therapies
CBT and ST are individual outpatient treatments of 20
sessions over 9 months (7 sessions in the first seven
weeks, followed by 13 fortnightly sessions)
CBT as well as ST will be conducted by specifically
trained psychotherapists on the basis of a treatment man-
ual. Each therapist conducts both the CBT and the ST
treatment. In order to take responsibility as study psy-
chotherapist, staff members have to have at least one
year of clinical experience as clinical psychologist or resi-
dent in psychiatry. In addition, they have to be enrolled
in formal training programs for cognitive behavioural
therapy or have to have completed their formal training.
In the case of interruptions of the study therapies due
to rehospitalisation of patients, holidays, other illnesses
of patients, illness of therapists etc. the treatment will
be continued as soon as possible. However, continuation
is only possible within a time frame of 9 months after
study inclusion. Thus, within 9 months after study
inclusion interruptions of participation will not result in
termination of the study treatment, exclusion from the
study or a new screening. When continuing the treat-
ment the remaining sessions will be scheduled on a
weekly basis as long as necessary. Thus, even patients
with longer interruptions will have the chance of getting
a maximum of the 20 sessions. In each case, study
therapies have to be terminated 9 months after study
inclusion (primary endpoint).
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Treatment plan
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Hallucinations  Dysfunctional 
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Social integration 
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- reevaluation of the 
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hallucinations
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processing, eg. 
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- defectiveness 
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expectations and 
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competences
Figure 4 Cognitive Behavioural Therapy - Overview.
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The primary endpoint for the biometrical evaluation of
the therapy is the Positive Score of the Positive and
Negative Syndrome Scale (PANSS, [22-24]). This
psychopathological rating scale represents a common
standard rating used in a wide range of outcome studies
in schizophrenia. It will be assessed 9 months after
inclusion of the participant.
The PANSS positive score is defined by seven items of
the PANSS (P1 - P7), all 7-point rated with higher
scores representing increasing levels of psychopathology.
It will be computed as the mean of these seven items in
order to provide a score that is easy to interpret on the
scale of a single item.
The German version of the PANSS was evaluated for
interrater reliability by Müller et al. [25] and was used
for the assessment of the primary endpoint by most of
the studies of the German Research Network on Schizo-
phrenia [26].
For the purpose of this trial PANSS is regarded as a
validated assessment instrument for positive symptoms.
No own validation studies on the PANSS will be con-
ducted. Moreover, the normal distribution and other pre-
requisites for parametric analyses (e.g. interval scale type)
of the PANSS positive-syndrome score will be assumed.
In order to ensure the interrater reliability of the rater
responsible for patient assessments in this study, the
raters will be trained for PANSS-rating. At the end of
the training the interrater reliability between the raters
will be assessed using videotaped interviews. Three
videos will be assessed by all raters and the reliability
will be statistically evaluated by the intraclass correlation
coefficient (ICC). The reliability will be regarded as
acceptable if the ICC of the PANSS-positive score will
be .8 or higher. If the ICC is lower than .8 the rater
training will be continued until the criterion is fulfilled.
Assessment for reliability will be repeated in case of any
change of raters.
During the course of the study the interrater reliability
will be assessed regularly every year in order to analyse
rater shift. It will be reported whether raters demon-
strate a tendency of higher or lower ratings at the end
of the study.
As persistent positive symptoms are chronic symp-
toms which change very slowly a two-year follow-up
after completion of treatment will be conducted. The
primary endpoint will be analysed also at the end of the
follow-up period.
Endpoints of Safety
Endpoints of safety are
￿ Death caused by suicide
￿ Suicide attempt
￿ Suicidal crisis (explicit plan for serious suicidal
activity without suicide attempt) as defined in
Engagement 
Assessment and shared formulation 
Treatment plan  
Topics Strategies 
Therapeutic 
relationship 
relaxed 
atmosphere 
humor 
empathy 
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disclosure of the 
therapist 
affirmation 
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patients’ 
autonomy 
- Work 
- School 
- Living situation 
- Hobbies 
- Friends 
- Family 
- Physical health 
- Financial situation 
- Grooming 
- Every-day duties 
- Neighborhood
- Enhancement of self-esteem 
- Activation of external ressources 
- Counseling & intstruction 
- Implicit problem solving 
- Structuring
Figure 5 Supportive Therapy - Overview.
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[CDSS; [27]], item 8, rating 2)
￿ Severe symptomatic exacerbation, defined by the
Clinical Global Impression Scale (CGI) which
includes ratings of illness severity, changes in overall
clinical status, and therapeutic effects. A rating of
CGI2 ≥ 6 and CGI 1≥ 6 would be regarded as severe
adverse event.
Information about these safety parameters is recorded
in the CRF every four weeks by the study rater as part
of the regular clinical assessment.
Secondary Endpoints
A complete overview over the endpoints of this trial is
given in Table 2. Secondary endpoints will cover addi-
tional aspects of outcome, such as the course of symp-
toms and insight into the disorder. Results regarding
secondary outcomes will only be interpreted as explora-
torily. In particular, PSYRATS [28] provides information
about the distress caused by symptoms, AMDP [29]
provides additional information about the content of
delusions, and SUMD [30] allows for a more detailed
analysis of the patient’s self awareness regarding symp-
toms, i.e. insight.
Treatment effects in the field of psychiatric disorders
should always be assessed al s of r o mt h ev i e w p o i n to f
the patient. However, a disorder of self evaluation is
p a r to ft h ep o s i t i v es y n d r o m ew h i c hi st h er e a s o nf o r
choosing observer ratings as primary endpoint. On the
other hand, the general rating of patients about their
symptoms is important and is represented by the follow-
ing secondary endpoint.
The Symptom Checklist [SCL-90-R; [31]] assesses
subjectively felt impairments due to somatic and psychic
symptoms within a frame of seven days. The SCL-90-R
for example also assesses psychotic or depressive symp-
toms. Thus, self ratings of these symptom dimensions
seem to be a sensible completion of symptom ratings.
As CBT is supposed to reduce symptoms we hypothe-
size, that SCL-scores will be lower in CBT compared to
ST at T9.
Low self-esteem might be viewed as a product of the
schizophrenic patient’s experience of positive as well as
Table 2 Timing of assessments of endpoints for safety and efficacy
T0 T1,2 T3 T4,5 T6 T7,8 T9 F1 F2 F3 F4
pre treatment phase
(monthly assessments)
post follow-up
(every 6 months)
Month 0 1,2 3 4,5 6 7,8 9 15 21 27 33
Inclusion Assessment
Structured Clinical Interview for DSM-IV x
Anamnestic interview x
Safety
Severe Adverse Event asessment
1 xxxxx xxxxx
CDSS [27] x xxxxx xxxxx
Clincal Global Impression (CGI) xxxxx xxxxx
Efficacy
PANSS [22] x xxxxx xxxxx
PSYRATS [28] x xxxxx xxxxx
GAF and Social Status x xxxxx xxxxx
Blindness Protocol x xxxxx xxxxx
CSSRI
3 [ 6 1 ] x x x x xxxx
EQ-5D [64] x x x x xxxx
SUMD [30] x x x x
AMDP-psychosis items
2 [29] x x x x
Side effect rating scale [65] x x x
SCL-90-R [31] x x x x
FSKN [33] x x x x
Neuropsychological test battery x x
1Suicide, Suicide attempts,
2 items 33-58,
3includes assessment of medication and medication compliance; CDSS: Calgary Depression Scale for Schizophrenia;
PANSS: Positive and Negative Syndrome Scale; PSYRATS: Psychotic Symptom Rating Scales; GAF: Global Assessment of Functioning; CSSRI: Client
Sociodemographic and Service Receipt Inventory; EQ-5D: Euro Quality of Life - 5 Dimensions; SUMD: Scale to Assess Unawareness of Mental Disorder; SCL:
Symptom Check List; FSKN: Frankfurter Selbstkonzeptskalen (Frankfurt Self-Concept Scales).
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quences [32]. On this background, the self concepts as
measured by the Frankfurt Self-Concept Scales [FSKN,
[33]] will be assessed. The subscales of this self rating
questionnaire assess attitudes towards the own person
(e.g. self esteem). Cognitive behavioural therapy might
have a beneficial impact on self-esteem in schizophrenic
patients [32]. Since self concepts do usually change
slowly the FSKN will only be applied at baseline, post-
treatment, 6-month follow-up, and 12-month follow-up.
Traditional instruments that measure self-esteem may
not relate directly to the schema construct as outlined
in recent cognitive models. The Brief Core Schema
Scales [BCSS; [34]] aim to provide a theoretically coher-
ent self-report assessment of schemata concerning self
and others in psychosis. The scales assess four dimen-
sions of self and other evaluation: negative-self, positive-
self, negative-other, positive-other. The BCSS will be
applied at the same assessment points as the FSKN.
Quality control/Monitoring
As an instrument for quality control and quality assur-
ance the clinical trial will be monitored. Monitoring will
be performed by the Coordination Centre for Clinical
Trials at University Hospital Tuebingen (CenTrial)
according existing standard operating procedures
(SOPs). The purposes of the monitoring are to verify
that the rights and well-being of the subjects are pro-
tected, that the reported trial data are accurate, com-
plete, and verifiable from source documents, and that
the conduct of the trial is in compliance with the study
protocol/amendments, with GCP, and with applicable
regulatory requirements. The extent and nature of the
monitoring will be determined in a monitoring manual
before starting the trial. For every on-site visit a moni-
toring report will be submitted to the sponsor. Status
reports of the monitor will inform the sponsor regularly
about the actual status in the trial sites.
Data Management
Case report forms must be completed according to the
following schedule:
a) Before the treatment starts: the patient must be
screened/randomised at CenTrial. For that purpose all
relevant data must be reported.
b) Documentation of the treatment and follow-up
visits: Each visit should be documented immediately.
c) Upon occurrence of a Severe Adverse Event (SAE)
All SAEs occurring during the observation period of 9
months must be reported by fax to the sponsor’sm e d i -
cal expert, the medical director of the Department of
Psychiatry and Psychotherapy of the University of
Tuebingen. All forms must be dated and signed by the
responsible investigator or one of his/her authorized
staff members.
T h i ss t u d yi sd e s i g n e dt ob ed o c u m e n t e dm a i n l yv i a
internet. The study software koordobas, an Oracle-based
application of the IMB, will be used for the data man-
agement. This application was in full compliance with
GCP-requirements (e.g. audit trail, validation) at the
start of the trial. The eCRF data are reported by author-
ized investigators via internet on the specific case report
forms (eCRFs). The case report forms (eCRFs) must be
completed, dated and signed electronically by the inves-
tigator or one of his/her authorized staff members as
soon as the requested information is available. The list
of staff members authorized to sign case report forms
(with a sample of their signature) have been sent to
CenTrial by the responsible investigators before the
start of the study.
In all cases, it remains the responsibility of the investi-
gator to check that case report forms are completely
and correctly filled in. The data manager will perform
extensive consistency checks on the eCRFs and issue
Query Forms in case of inconsistent data. Those Query
Forms must be immediately answered and signed by the
investigator (or an authorized staff member). The origi-
nal must be returned to CenTrial and a copy must be
appended to the investigator’s copy of the eCRFs.
If an investigator (or an authorized staff member)
n e e d st om o d i f ya ne C R Fa f t e rt h eo r i g i n a le C R Fh a s
been filled in and returned, he/she can change it by
notifying the Data Centre electronically appending a
print out of the notification to his own copy of the
eCRFs. All modifications will be protocolled by the
audit trail of the study software.
All study related data (electronic as well as on paper)
will be stored for 10 years in the archive of the Depart-
ment of Psychiatry and Psychotherapy, University of
Tuebingen.
The audio tapes of therapy sessions will be stored in
locked filing cabinets. They are to be labeled with the
patients ID only. Access to the audio tapes is permitted
only with written permission of the principal investiga-
tor. The audio tapes will be destroyed after finishing the
data analysis.
Assessment, storing, processing, and deleting of per-
son related data will be conducted in accordance to
German law.
Sample size calculation
The primary endpoint analysis will be conducted with
linear mixed models (LMM, [35]). As software for sample
size calculation for the analysis of longitudinal data using
multilevel mixed models is not available, we calculated
the sample size for classical ANOVA using nQuery 4.0.
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about CBT for persistent positive symptoms. For the
comparison between CBT and TAU Tarrier et al. [36]
reported Effect Sizes (ES: (meanTAU-meanCBT)/SDTAU)o f
0.33-0.66 for the 18 month follow-up. Tarrier et al.
(1998) found an ES of 0.48, Kuipers et al. [37] an ES of
0.6, and Sensky et al. [19] an ES of 0.5. In a review Gould
et al. [38] found a range of ES from 0.2 to 1.26. The
reported variance differs to a great extent indicating con-
siderable differences with regard to samples or treat-
ments. A recent effect size analysis applied broader
inclusion criteria for studies and resulted in an ES of .57
for acute patients (post-treatment analysis) and an ES of
0.27 in chronic patients [3]. These reviews show consid-
erable efficacy of CBT when compared to treatment as
usual. However, this study focuses on the difference
between CBT and Supportive Treatment (ST). Unfortu-
nately, the power calculation is more difficult for this
comparison as fewer studies are available. According to a
review of Tarrier et al. [36] the following studies have
included ST-control groups: Tarrier et al. [18], Haddock
et al. [28], Pinto et al. [39], Lewis et al. [40], and Durham
et al. [41]. The effect sizes vary between -.49 in a study
including only 21 patients [28] and .99 in a study with 37
patients [39]. In addition, sample characteristics and end-
points are different between the studies. Thus, it does not
seem possible to make assumptions about the ES for the
comparison between CBT and ST based on the literature.
Regarding drop out rates there is also much heteroge-
neity with a range between 0% and 36% [36,38]. The
majority of studies reports drop out rates of less than
20%. As measures of quality control will be applied and
monetary incentives for participation in the follow-up
examinations will be offered we expect a drop out rate
of about 20%.
On this background we aim to identify an effect size
of more than .35 as significant given an anticipated drop
o u tr a t eo f2 0 % .A nE So f. 3 5w o u l db eo b t a i n e di ft h e
PANSS Scores (Positive Syndrome) at the post treat-
ment assessment were 12 for CBT and 14.5 for ST with
a standard deviation of 7.14. An ES of less than .35
would be of limited clinical relevance.
T h i sr e s u l t si nn=1 3 0p e rg r o u pf o rap o w e ro f8 0 %
and a two-sided significance level of 5% (sample size cal-
culated by nQuery 4.0, Panel MGT0). The confirmatory
statistical analysis will be based on the intention-to-treat
principle. Patients with missing PANSS-scores at T9
(post-treatment) will be included with the last observa-
tion carried forward (LOCF). In case of missing PANSS-
scores at T9 the treatment effect will presumably be
underestimated by using LOCF. To compensate for this
underestimation the sample size should be adapted for
drop out. Thus, we plan to include 330 patients (165
per study condition).
As assumptions about the real effect size cannot be
based upon the literature we calculated different scenar-
ios: in case of a lower effect size and/or drop out of
more than 20% the statistical power will be reduced. For
example, a reduced ES of 0.2 would result in a power of
only 36% for the drop out of 20%. An increased drop
out of 30%would reduce the power to 74% for the mini-
mum ES of .35. On the other hand, a more favourable
ES of 0.45 would increase the power to 85% for the
maximum drop-out rate of 20%.
With a sample size of 330 individuals (165 each therapy
group), ten assessments per patient, one primary analysis
variable (therapy) and one covariable (center), the power
should also be sufficient for a Mixed Model [42].
Table 3 gives an overview over the number of patients
required in the different stages of the trial and the
required effort for treatment and assessment. In order
to successfully include 330 patients 6 study centers have
been included which were committed to participate
actively in this trial.
Statistical Analysis
The primary endpoint for the biometrical evaluation
(responsible statistician: CM) is the PANSS-Positive-
S c o r eo ft h eP o s i t i v ea n dN e g a t i v eS y n d r o m eS c a l ea t
the time of 9 months after inclusion. It will be analysed
after completion of T9-assessments.
The statistical hypothesis for the confirmatory test of
the primary endpoint is that the treatment groups are
significantly different when analysed using multilevel lin-
ear mixed models with treatment and study centres as
levels of analysis and adjustment for baseline values.
The decision for maintaining or rejecting the null
hypothesis will be made applying a two-sided test with
a = 0.05. A two-sided test will be chosen as the pub-
lished results about the comparison of CBT and ST are
inconsistent. The observed effects will be described by
use of means including the appropriate (one-sided)
95%-confidence intervals.
The confirmatory statistical evaluation of the efficacy
of the CBT in this trial will be restricted to the primary
Table 3 number of patients required in the different
stages of the trial
total per
center
required number of eligible patients (with 75%
refusal)
1304 217
number of patients to be included (incl. 20% drop
out)
330 55
number of patients to be analysed (ITT, LOCF) 330 55
number of patients to be analysed per protocol 260 44
treatment sessions (CBT and ST) 5530 922
number of visits 4620 770
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be interpreted as statistical evidence for the efficacy of
CBT. The confirmatory statistical analysis will be based
on the intention-to-treat principle (ITT). In addition, a
“per protocol” (PP) analysis will be conducted
All secondary endpoints will be compared and statisti-
cally assessed for descriptive purposes and not in a con-
firmatory sense. The aim of the analysis is explorative
data analysis, not hypothesis testing or generation of evi-
dence for efficacy. Because of the explorative character
of this part of the analysis, no a priori statistical analysis
plan exists. If adequate, secondary endpoints will be
compared and statistically assessed using covariance
techniques with baseline values and centers as covari-
ates. Changes of scores over time will be modeled using
linear or non-linear or nonparametric models as ade-
quate. In addition, appropriate statistical methods of
explorative data analysis including graphical methods
and descriptive statistics will be used. No interim analy-
sis and no subgroup analyses are planned.
Medication
Regarding psychopharmacological treatment the study is
open and requires no restriction of treatment. The sam-
p l es i z eo ft h i st r i a l sj u s t i f i es the expectation of equal
distribution of type (classical vs. atypical antipsychotics),
dose, rate of non-adherence to medication, prescription
of other psychopharmacological treatment (antidepres-
sants, mood stabilizers, benzodiazepines) in both treat-
ment groups.
However, both the medication dose and the medica-
tion compliance are potentialc o n f o u n d e r sw h i c hh a v e
to be controlled for. In particular, it could be the case
that medication will not be completely independent
from the study condition. As medication has the poten-
tial to influence the course of symptoms it is important
to observe the medication carefully to allow for detailed
analysis of this aspect. Medications and doses will be
documented monthly. Side effects will be assessed at
baseline as well as at the post-treatment assessment T9.
Medication compliance [43] will be rated monthly
along a 7-point scale (with 1 = total rejection of medica-
tion, and 7 = active cooperation and full acceptance of
medication).
Assessment of adherence to treatment manuals
To evaluate the adherence to the manuals a number of
measures will be assessed. First, in order to systemati-
cally assess characteristics of form and content as well
as aspects of adherence of treatment therapists filled in
structured session reports after each treatment session.
The session reports give information whether the treat-
ment session was conducted as scheduled or cancelled by
the patient and whether the session began on time or
delayed. Further, the session reports show the duration of
the session, the primary and secondary foci of interven-
tion (e.g. establishing treatment goals, work on delu-
sions), the use of manualized treatment material, reasons
for non-adherence to the agenda (e.g. due to sympto-
matic worsening, focus on current problems, non-com-
pliance of patient or other reasons), accomplishment of
homework by the patient, and the cooperation of the
patient as rated by the therapist. The cooperation rating
scale is a fully anchored ordinal scale with 1 = excellent,
2 = adequate, 3 = sufficient, and 4 = poor. The session
reports will be available for all sessions conducted. An
individual study therapy will be considered as having
been conducted according to manual if a patient has
attended at least 14 treatment sessions. Further, two
thirds of the sessions conducted have to fulfil the follow-
ing criteria: duration >40 and <60 minutes, use of man-
ualized treatment materials or strategies, and at least
sufficient cooperation of the patient.
Second, all treatment sessions (CBT and ST condition)
will be audio taped if patients give their consent.
A maximum of four audio tapes of each patient will
randomly be selected for analyses: one of the first 3 ses-
sions (early phase), one of the sessions 4-10 (early mid-
dle phase), one of the sessions 11-17 (late middle
phase), and one of the last 3 sessions (late phase). This
procedure is independent of the actual number of treat-
ment session a patient has participated in. The audio
tapes will be checked with regard to manual adherence.
Guided by a checklist it will be assessed whether or not
the treatment session followed the CBT or the ST man-
ual with regard to content, the material worked on, and
the formal characteristics (e.g. duration of the session).
The ST checklist also comprises items regarding an irre-
gular application of CBT-specific techniques. Our adher-
ence checklists will be subjected to analysis of interrater
reliability. Since mistrust and paranoia are core symp-
toms of chronic psychotic disorders, we expect a rate
considerably below 100% of patients who give their writ-
ten informed consent for audio taping their therapy.
Assessment of unspecific mechanisms of action
According to Orlinsky’s and colleagues’ review [16] the
strongest evidence linking process to outcome concerns
the therapeutic alliance. Therapeutic alliance proved to
be a common ingredient of all psychotherapeutic inter-
ventions [44] and to be at least modestly correlated with
outcome [45,46]. The therapeutic alliance as well as
other unspecific mechanisms of action (e.g. clarification,
activation of resources, emotional involvement, problem
solving) will be assessed using the Bernese Post Session
Reports [47] for patients (BPSR-P) and therapists
(BPSR-T). In the framework of the German Research
Network on Schizophrenia we conducted factor analyses
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patients with schizophrenia participating in CBT for
relapse prevention. We identified dimensions relating to
the therapeutic alliance, therapy progress, emotional
involvement, dissatisfaction with therapy, and others.
Both instruments will be applied at the end of each
therapy session of the CBT and the ST condition. The
continuous application of the session reports will allow
examining the course of the above mentioned unspecific
therapeutic mechanisms during the CBT and ST. We
expect no differential course of these unspecific factors
between the two treatment conditions.
Assessment of therapist’s competence
Establishing empirical collaboration between the patient
and the therapist as a means for cognitive restructuring
is a major aspect of the therapists’ competence in CBT.
To measure the extent of empirical collaboration the
four randomly selected audio tapes will be analysed by
means of the Cognitive Therapy Scale for Psychosis
[CTS-Psy; [48]]. The CTS-Psy consists of two subscales
each with five items. The items are rated on the original
nominal scale (1 = appropriately included, 0 = inappro-
priately omitted, and 9 = appropriately omitted) as wells
as on a 5-point interval scale where higher scores indi-
cate better competency. We designed this 5-point
Likert-scale to prevent potential ceiling effects. Scale I
“general skills” includes the items agenda setting, feed-
back, understanding, interpersonal effectiveness, and
collaboration; scale II “specific skills” covers guided dis-
covery, focus on key cognitions, choice of intervention,
homework, and quality of intervention. The specific
skills will be measured only in the CBT condition. The
CTS-Psy demonstrates excellent inter-rater reliability,
good validity, and sensitivity to changes [48]. Further-
more, we will conduct own analyses on the interrater
reliablity of our German adaptation of the CTS-Psy.
Regarding the application of general skills we expect
no difference between the CBT and the ST condition.
Further, according to the rationale of CBT, we hypothe-
size that the quality of a therapist’s specific skills corre-
lates with therapeutic outcome (symptom reduction) in
the CBT condition.
The research addressing treatment adherence, the
unspecific mechanisms of action, as well as the thera-
pist’s competence are integrated within the sub-project
“Process and outcome in CBT for positive symptoms in
psychotic disorders” (PI: AW).
Assessment of safety of interventions during the
treatment phase
Safety of psychological intervention in schizophrenia has
been assessed in terms of suicide rates and rates of ser-
ious symptom deteriorations. The Cochrane Reviews on
Family Intervention [49], onC o g n i t i v eB e h a v i o u r a l
Treatment of Positive Symptoms [50], on Cognitive
Remediation [51], and on Psychoeducation [52] could
demonstrate that neither the suicide rate nor the rate of
relapse was increased in psychological intervention. The
same result was reported by Tarrier et al [7] who con-
ducted the most subtle analysis yet on this topic and
included also an ST condition in their study. Thus,
there is no indication in the literature for an increased
risk for patients as a consequence of their participation
in the treatment described in this protocol. However,
based on clinical experience it seems important to con-
sider the following major risks:
(a) Increase of positive symptoms as a consequence of
therapeutic overstimulation: It is known that positive
symptoms may increase if the psychosocial stress is
greater than the coping ability of a patient. Thus, a
forced therapeutic approach may represent stress for a
patient increasing the risk for symptom exacerbation.
(b) Suicide, suicide attempt or suicidal crisis could
occur as a consequence of dysfunctional coping with the
negative psychological and social consequences of the
disorder.
However, this study provides optimal conditions to
prevent major risks, to detect symptom exacerbations
early, and to intervene early and sufficiently. (a) The
symptoms are assessed frequently in short intervals by
the rater as well as by the study therapist. (b) Therapists
are trained to react to symptom deterioration. They will
adapt their strategy to the patients’ needs. This is com-
pletely compatible with the treatment manual. (c) The
therapist will discuss the treatment strategy with clini-
cally experienced supervisors. (d) A psychiatrist respon-
s i b l ef o rr o u t i n ec a r ei si n v o l v e di nt h et r e a t m e n t .
Independent of the study this psychiatrist will initiate
crisis intervention whenever required.
As described above there is no indication for specific
risks or enhanced rates of adverse events as a conse-
quence of participation in CBT or ST. However, as the
safety of interventions for positive symptoms in schizo-
phrenia have not been studied extensively this study will
control for severe symptom exacerbations and suicidal
crises as adverse events.
Severe adverse events to be observed at every assess-
ment throughout the trial are:
￿ Death caused by suicide
￿ Suicide attempt
￿ Suicidal crisis (explicit plan for serious suicidal
activity without suicide attempt) as defined in Cal-
gary Depression Rating Scale for Schizophrenia
[CDSS; [27]], item 8, rating 2)
￿ Severe symptomatic exacerbation, defined by the
Clinical Global Impression Scale (CGI) which
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clinical status, and therapeutic effects. A rating of
CGI2 ≥ 6 and CGI 1≥ 6 would be regarded as severe
adverse event.
The safety parameters are part of the regular clinical
follow-up examination conducted by the study rater
every four weeks. In addition, study participants remain
in their usual routine outpatient treatment and will
therefore see their independent psychiatrist regularly.
The routine care psychiatrist and the study therapist
are requested to exchange information about the status
of the patient and to provide an optimal individual
treatment. The study rater will communicate any infor-
mation about adverse events to the routine care psychia-
trist and the study therapist. Thus, the study provides an
optimal framework to immediately detect any complica-
tion in the treatment.
Information about the safety parameters is recorded in
the CRF every four weeks by the study rater. In addi-
tion, therapists are requested to assess the safety para-
meters in every session and to record their assessment
in the session protocol.
The observation of these events should result in a sta-
tistical remarkable result, if the incidence of events in
one of the two groups will be higher than in the other
group. The statistical observation will be done for a sig-
nificance level of a = 0.2 (two sided) and a power of 0.8
with the help of the software PEST (distributed by
Whitehead).
Analyses will be conducted three times: after 100, 200
and 300 patients reaching T3. When analysing the safety
data, the full observation period of all patients and all
available data will be considered. The safety analyses
will be conducted by a statistician (CE) not involved in
the design and analysis of this trial, using coded group
labels A and B blinded for the real therapy groups.
The results will be reported directly to the members
of the independent advisory board. In case of rejection
of the null hypothesis of equal incidence rates in the
two groups, the advisory board will decide whether or
not the study has to be stopped.
We do not expect any difference regarding illness
related events between the groups.
Time schedule of the study and duration of subject
participation
Table 4 gives an overview over major phases of this trial.
A long preparation phase was necessary due to the mul-
ticenter design and the requirements of a publicly
funded clinical trial. The recruitment phase was com-
pleted in January 2010. The recruitment phase had to
be extended as the availability of patients who where
willing to give consent was limited in some study
centers. However, the designed sample size could be
included and the post-treatment assessments (T9) will
be finalized in October 2010. Analyses of major out-
come will begin in November 2010. Long-term follow-
up data will be collected until October 2012.
A single patient participates for a duration of 33
months consisting of the treatment phase (9 month)
and the follow-up phase (24 months). The time of “first
patient in” until “last patient out” will be 67 months.
Funding, role of funders, and “sponsor” responsibilities
This study is publicly funded by the German Federal
Ministry of Education and Research (Bundesministerium
für Bildung und Forschung, BMBF), project number
01GV0618. The study is part of the BMBF research pro-
gram “Research Networks on Psychotherapy”. The fund-
ing agency selected projects on the basis of the vote of
an international review board. It does not exert any
influence during the trial. The responsibilities of the
“Sponsor” in terms of the guidelines of good clinical
practice in clinical trials (ICH-GCP, E6) has been taken
by the University Hospital of the University of Tübingen
which delegated responsibility to the head of department
of Psychiatry and Psychotherapy.
Associated research
Cognitive deficits and biases
For the assessment of neurocognitive deficits, a short
and reliable neuropsychological battery consisting of
tests measuring verbal intelligence, attention, executive
functions, and memory is administered. This battery has
been widely employed in the BMBF funded German
Research Network on Schizophrenia [53] and a substan-
tial database on the relationship of cognitive deficits
with psychopathological symptoms, course of illness,
and response to therapy has been gathered [54]. The
assessment of cognitive biases or cognitive styles is an
emerging field of research, and several experimental
studies have found evidence of specifically altered per-
formance in delusional subjects [55,56]. Therefore, the
sub-processes of social cognition which might serve as
mediating mechanisms will be assessed in detail in the
Table 4 Study phases
Phase Time
Grant application and preparation March 2005 - March
2007
Recruitment April 2007 - January
2010
Treatment completion and completion of post
treatment assessment
February 2010 -
October 2010
Follow-up until 24 months after treatment November 2010 -
October 2012
Start of Analysis of primary outcomes November 2010
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underlying delusional symptoms and therapeutic
change” (PI: MW). Attribution style is assessed with the
Internal, Personal and Situational Attribution Question-
naire [IPSAQ; [57]]. Usually, the attributional style of
paranoid patients is alteredi nt h a tt h e y ,s i m i l a rt o
depressed patients, make global and stable explanations
for negative events, but, unlike depressives, they prefer-
entially assume external causes, and particularly other
people to be responsible [8]. Another aspect of dis-
turbed inferential thinking relates to the evaluation of
hypotheses. In tasks requiring one to make a good guess
based on prior evidence, paranoid patients jump to con-
clusions prematurely, as if they need less evidence to be
sure (this style has been termed epistemological impul-
sivity). One method to assess such a reasoning style is
the Beads in a Jar Task of Garety and colleagues [58];
an adapted computer version of this task [59] is
e m p l o y e dh e r e .F i n a l l y ,s t a ndardized pictures from the
Pictures of Facial Affect set [PFA; [60]] are applied to
assess accuracy and speed of facial affect recognition.
Neural correlates of cognitive biases
A functional magnetic resonance imaging (fMRI) study
(PI: TK) investigates major mediating factors of Black-
wood’s model. Using fMRI differential effects of CBT
and ST on cerebral activation is being investigated. The
present study investigates neurophysiological processes
underlying the development and amelioration of symp-
toms of delusion. The neural correlates of jumping to
conclusions and attributional bias will be investigated.
The paradigms of the fMRI study will be complemen-
tary to those applied in a larger sample via neuropsy-
chological experiments outside the scanner. Extensive
reliability and quality control measurements ensure the
validity of data across different centres. The following
questions will be addressed: What are the neural corre-
lates of delusions taped by the dysfunctional processes
of attributional bias and jumping to conclusions? Can
future therapeutic success be predicted on the basis of
specific brain activation patterns already before treat-
ment? Which components of neural circuits can poten-
tially by altered by CBT? Are there distinct brain
structures that can be linked to delusions?
Cost effectiveness
An associated project assesses the cost effectiveness of
the treatment (PI: HHK). The direct and indirect costs
of both study arms are calculated prior, during and after
therapy using a modified version of the „Client Sociode-
mographic and Service Receipt Inventory” [61]. The
CSSRI assesses the overall resource utilization of
patients as well as productivity losses. To estimate costs
these quantities are then valued with market prices.
When market prices are not available administrative
prices or mean costs are used to estimate so called
“shadow prices”.
To assess the health effects of CBT and ST, two dif-
ferent measures are used. On the one hand the EQ-5D
[62], a generic measure of subjective health related qual-
ity of life comprising a health profile and a visual analo-
gue scale is used prior, during and after therapy. From
the EQ-5 D, health state utilities are derived to calculate
quality adjusted life years (QALYs) [63]. On the other
hand an objective measure of positive symptoms
(PANSS-Score) is used to quantify treatment response.
A Markov model is built to estimate the ICER using
long term costs and effects beyond the time frame of
the study. Markov models simulate the course of a dis-
ease over time and thus allows for calculating long term
costs and effects.
Adaptation of CBT for adolescents
This sub-project (principal investigator: AB) represents a
pilot study which focuses on the evaluation of exten-
sions of CBT for adolescents with early onset psychosis
(EOP). Objectives are to develop a modified CBT
(mCBT) for adolescents with EOP, to explore its accep-
t a n c ea n df e a s i b i l i t ya n dt op r o v i d ed a t af o rar e a l i s t i c
estimation of achievable effect size. The study is a multi-
center, prospective, parallel group, randomised con-
trolled trial. Forty-two patients will be recruited. All
participants will receive individual optimised psychiatric
treatment as usual (TAU). mCBT will be provided for
50% of the patients (n = 21) in addition to TAU. mCBT
is an outpatient treatment which consists of 20 indivi-
dual sessions in nine months and five psychoeducation
sessions with parents. All sessions will be conducted by
specifically trained psychotherapists on the basis of a
treatment manual.
The primary endpoint will be the positive syndrome of
the PANSS at T9 (post treatment assessment). Monthly
assessments during the treatment phase will closely
monitor the course of symptoms. Patients have to fulfil
DSM-IV criteria of schizophrenia, schizoaffective disor-
der, or delusional disorder, confirmed by a structured
clinical interview (SCID-I). Decisive for inclusion is a
score of 4 or more on the PANSS-items “Delusions”
(P1) or “Hallucinations” (P3) or „Unusual thought con-
tent” (G9) representing a moderate or severe symptom
intensity. Furthermore the presence of positive symp-
toms for at least four weeks or more is necessary.
Discussion
Relevance of the POSITIVE study
This clinical trial is part of efforts to intensify
psychotherapy research in the field of psychosis in Ger-
many, to contribute to the international discussion on
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ment psychotherapy in routine care. Furthermore, the
study will allow drawing conclusions about the media-
tors of treatment effects of CBT of psychotic disorders.
In an innovative approach the network combines clini-
cal trials on the efficacy of CBT with research designed
to analyse active ingredients of the treatment. The
POSITIVE Study will presumably be the largest full
scale clinical trial comparing CBT with ST. This com-
parison will allow drawing conclusions about the speci-
fic efficacy of CBT for the treatment of persistent
positive symptoms in psychotic disorders. The projects
of the research network will give information about the
processes of CBT, the effects of CBT on cognitive biases
as well as the neural basis of theses biases. The latter
have not yet been studied, in particular with respect to
treatment outcome. Further, a full economic evaluation
of CBT will be conducted. To this day, no such data on
cost effectiveness are available yet.
Strength of the POSITIVE study design
There are several strengths of our study design. To
summarize, within a multicenter design a systematic
recruitment procedure with clear inclusion criteria is
implemented. Randomisation is applied independent of
investigators and therapists. The study is single blind
and the success of blinding will be assessed a posteriori.
Reliability checks for the primary endpoint have been
conducted prior to the first patient inclusion and there-
a f t e ro n c eay e a r .T h u s ,w ew i l lb ea b l et oc o n t r o lf o r
intra-rater shift over time.
Further, assessment and analysis of severe adverse
events is a crucial component of the POSITIVE Study.
Thus, our clinical trial will be the first which gives
detailed information about the safety of CBT on persis-
tent positive symptoms.
As an instrument for quality control and quality assur-
ance the clinical trial will be monitored by a Coordina-
tion Centre for Clinical Trials. Manualized treatments
with predefined adherence checks, regular supervision,
and process-outcome analyses assure the quality of the
study therapies.
Finally, the POSITIVE study provides an adequate
sample size for the expected moderate treatment effect,
has a predefined primary endpoint and multilevel sec-
ondary endpoints. The elaborated statistical analysis will
be done by an external statistician.
Lines of interpretation
There are two main lines of interpretation of the results
of POSITIVE study.
First, according to our hypothesis, CBT might be
superior to ST with regard to the reduction of positive
symptoms. This result will be interpreted as an evidence
for the specific efficacy of CBT. In this case it will be
interesting, whether the cognitive biases (e.g. jumping to
conclusions, external attribution style) have been chan-
ged and normalized in the CBT only and whether these
changes can also be observed on a neural level. A signif-
icant association of the change of the cognitive biases
on the one hand side and the change in positive symp-
toms on the other hand side would support the basic
assumption of CBT approaches that the cognitive biases
are factors which actually mediate the treatment effect.
In addition such a result would substantially support
psychological models of delusion formation [12] as it
would show that psychological processes are involved
not only in the development but also in the reduction of
positive symptoms. However, if changes in positive
symptoms are not associated with changes in biases
questions will arise regarding the hypothesised mechan-
ism of action in CBT. The health economical analysis
will add an additional aspect of evaluation as it will
focus on cost effectiveness and not on efficacy.
Second, CBT and ST might show no significant differ-
ence regarding reduction of positive symptoms. In this
case CBT has no specific effect on positive symptoms
and symptom changes are independent of the investi-
gated psychotherapeutic treatments. As this trial does
not include a “treatment as usual” (TAU) condition in
order to maximise the statistical power the question will
remain open, whether CBT and ST had any effect on
positive symptoms. Effects of the “natural” course and
effects of medication can not be identified using the pre-
sent design. Even, if CBT and ST lead to comparable
changes in positive symptoms it will be important to
analyses changes in cognitive biases as these treatments
might build on different mechanisms of action.
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